Sponsors should contact clinical trial centers early and frequently if they want to successfully implement new technologies and manage the relationship “more as a partnership than a transaction,” says Silvina Baudino, director of location strategy at Teckro.
“Sites must have a voice” who work with vendors and sponsors from the start, and it is critical that the latter take the time to demonstrate the value of a proposed technology to the sites, notes Baudino. Communication and transparency are key, she adds, saying sponsors don’t always realize that what they think is an amazing technology “is actually going to add a lot more work to the website.”
“Site requirements have evolved during COVID-19 and we need to keep in mind that they are the end users of any test technology,” said Malia Lewin, Global Head of Strategy at Teckro. “We’re definitely seeing sponsors recognize that.”
For example, many sponsors Teckro works with have started variations on location satisfaction initiatives. “They want to be the sponsor of choice,” says Lewin, especially in crowded and competitive therapy areas like oncology studies. “Sponsors need to make sure the sites are happy,” she notes.
Webinar – Technology Push: A discussion about implementation problems, strategies and lessons learned
Join us on December 15 when Baudino, Lewin and other experts have a discussion on how the COVID-19 pandemic has driven technical implementation at the site level. The struggles, obstacles and insights from the location perspective will be discussed as well as the effects on the workforce and how we would all like to prepare for the future. As a reminder, this webinar is FREE for ACRP members!
Details about the program and registration>
“Sponsors are increasingly realizing the importance of hearing the voice of the website,” agrees Baudino. Sponsors need to realize how “overwhelming” it can be for some websites when new or updated technology comes into play, she says. “Sites in the minimum average [working with] 10 vendors with different technologies per study, ”she adds.
“Technology is here to stay,” although its use could easily wane as the COVID-19 pandemic wears off, Baudino observes. She sees hybrid rather than fully decentralized clinical trials in the coming years. “We all have to work together” so that these technologies are fully implemented and do not cause problems for the locations, she emphasizes.
Author: Michael Causey